Brooke JS. Stenotrophomonas maltophilia: an emerging
global opportunistic pathogen. Clin Microbiol Rev
2012;25(1):2–41.
Samonis G, Karageorgopoulos DE, Maraki S, Levis P,
Dimopoulou D, Spernovasilis NA, et al.
Stenotrophomonas maltophilia infections in a general
hospital: patient characteristics, antimicrobial
susceptibility, and treatment outcome. PLoS One
2012;7(5):e37375.
Dalamaga M, Karmaniolas K, Chavelas C, Liatis S,
Matekovits H, Migdalis I. Stenotrophomonas maltophilia:
a serious and rare complication in patients suffering from
burns. Burns 2003;29(7):711–3.
Falagas ME, Karageorgopoulos DE. Pandrug resistance
(PDR), extensive drug resistance (XDR), and multidrug
resistance (MDR) among Gram-negative bacilli: need for
international harmonization in terminology. Clin Infect
Dis 2008;46(7):1121–2.
Guyot A, Turton JF, Garner D. Outbreak of
Stenotrophomonas maltophilia on an intensive care unit. J
Hosp Infect 2013;85(4):303–7.
Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK,
Hsueh PR. Therapeutic options for Stenotroponas
malhomtophilia infections beyond co-trimoxazole: a
systematic review. J Antimicrob Chemother
2008;62(5):889–94.
Tsai WP, Chen CL, Ko WC, Pan SC. Stenotrophomonas
maltophilia bacteremia in burn patients. Burns
2006;32(2):155–8.
Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK,
Hsueh PR. Therapeutic options for Stenotroponas
malhomtophilia infections beyond co-trimoxazole: a
systematic review. J Antimicrob Chemother
2008;62(5):889–94.
Al-Jasser AM. Stenotrophomonas maltophilia resistant to
trimethoprim-sulfamethoxazole: an increasing problem.
Ann Clin Microbiol Antimicrob 2006;5:23.